Is Arcellx, Inc. (ACLX) a Buy, Sell, or Hold?
NASDAQ : ACLX
Arcellx, Inc.
$115.07 USD
$0.02 (0.02%)
- Volume
- 13.19M
- Average Volume
- 1.45M
- Market Capitalization
- $6.73B
- P/E Ratio
- -28.27
- Dividend Yield
- 0.00%
- Price Target
- $115.00
- Year High
- $115.13
- Year Low
- $50.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.44
| Source | Headline |
|---|---|
|
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and. businesswire.com - 2026-04-28 08:45:00 |
|
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year. zacks.com - 2026-04-27 10:45:59 |
|
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of “Hold” by Analysts
Arcellx, Inc. (NASDAQ: ACLX - Get Free Report) has been given an average rating of "Hold" by the nineteen research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, sixteen have issued a hold recommendation, one has given a buy recommendation and one has given a defenseworld.net - 2026-04-24 02:12:49 |
|
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expi. businesswire.com - 2026-04-17 08:30:00 |
